Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
North Simplistically speaking, Bavi is the ketchup and will work with whatever mustard is out there and improve SOC. IMHO
Never mind I am thinking of DITRA near Fort Belvoir
HMMMM near Fort Belvoir?
My wife worked for DARPA for a few years. Nope not small.
Jeff Boy does that story line sound familiar. My family members alone now own 240,000 shares. Last count about twenty plus more friends co-workers etc.have acquired shares. They know the risk/reward profile and choose to purchase.
LOOF If that rocket blast off next to your out house it is going to be messy. LOL
powerc Brads last tweet about PPHM on 3/23 was unfavorable. That was then will see what the future holds.
The Loncar Cancer Immunotherapy Index (LCINDX) seeks to track the combined performance of a basket of companies that develop therapies to treat cancer by harnessing the body's own immune system. Immunotherapy is a transformational field within the biotechnology space. The index will provide a metric to follow its progress as researchers advance new technologies for the benefit of courageous patients who fight the disease. It is an equal-weighted index containing both large pharmaceutical and growth-oriented biotechnology companies that are leading in this approach
It would be nice to be added to this index at some point.
Index Constituents
Novartis
Merck
Amgen
Bristol Myers
Celgene
AstraZeneca
Incyte
Juno Therapeutics
bluebird bio
Kite Pharma
Celldex Therapeutics
TESARO
NewLink Genetics
ZIOPHARM
Cellectis
MacroGenics
Bellicum
Five Prime Therapeutics
Atara Biotherapeutics
Sorrento Therapeutics
Agenus
Northwest Biotherapeutics
Lion Biotechnologies
Inovio Pharma
Advaxis
IFU Perhaps her work will come to light when bavi approved. You build a experienced qualified staff with this in mind. Will see. Thanks.
IFU I was not on this board in 8/14 so it benefited me. I hope a few others. Repeated, potentially good information can't hurt. Thanks
purp No Evidently this information has already been posted in the past
Wook was not aware this had already been posted before.
Bayer HealthCare Pharamcueticals
Partnering
Broad Networking for long-term success
To be able to develop innovative products, a company needs an appropriate environment – in Germany, in Europe and worldwide – and strong partners.
With a global network of external scientific and industrial development partners, we strengthen our own research infrastructure and, therefore, assure the long-term success of our product pipeline.
To supplement our internal efforts, we collaborate with several companies in different stages of the typical pharmaceutical research cycle.
Our more significant collaborations are described (in alphabetical order) in the table below.
Partner Objective
Affymetrix Understanding the disease mechanism and identifying new targets
ARTEMIS Pharmaceuticals GmbH In vivo validation of targets
Astra Zeneca Co-development of the selective estrogen receptor downregulator (SERD) for the treatment of hormonal dependent breast cancer
Avid Radiopharmaceuticals Radiopharmaceuticals compounds
Bausch&Lomb
SEGRA ophthalmology
Celera Genomic Cathepsin S inhibitor drug development program
ChemDiv Synthesis of compounds
ComGenex Synthesis of compounds
Genedata Expressionist software
Genzyme Corporation Campath in chronic lymphocytic leukemia and multiple sclerosis
Inpharmatica Kinase SARfari in Silico Drug Discovery
Johnson & Johnson Development of Rivaroxaban
Monash University New targets for gender health
MorphoSys AG Antibody diagnostics and therapeutics for cancer and other life threatening diseases
Nektar Therapeutics Targeted inhaled antibiotic therapy for pulmonary infections
Neurosciences Victoria Ltd. Treatment of neurodegenerative disorders
Novartis Pharma Research and development of inhibitors of angiogenesis
Nuvelo Development of alfimeprase
Onyx Co-development of Nexavar
Peregrine Pharmaceuticals, Inc. Selective cancer diagnostics (vascular targeting agents)
Philogen S.p.A. Development of immunoconjugates for cancer therapy and diagnosis
Proteros X-ray structure analysis
Regeneron Pharmaceuticals Development of the VEGF Trap for the treatment of eye diseases
Seattle Genetics Increasing the pool of potential drug candidates by biomolecules
Sonus Pharmaceuticals TOCOSOL Paclitaxel
Stanford University/Gambhir New PET tracers
Warner Chilcott SEGRA for dermatology
Mary J. Boyd, Ph.D.
Head of Business Development for Asia and Europe
Dr. Boyd has more than 20 years of international pharmaceutical and biotechnology business development experience with large pharmaceutical companies including GlaxoSmithKline, Novartis and Roche. Dr. Boyd was previously director, Asia, worldwide business development, R&D for GlaxoSmithKline; head of business development and licensing in Japan for Novartis; and head, licensing and patent group for Roche in Japan. In these positions, she identified new opportunities, negotiated global agreements and maintained productive relationships with other companies. Dr. Boyd holds a Ph.D. in Developmental Genetics from the University of Cambridge, UK and a B.Sc. in Biochemistry from the University of Sussex, UK.
With possible Global approval on the cusp she could be very busy.
Seagull Excellent reminder. The value is there for all to see if they choose to.
Happy Resurrection Day!
Our little Peregrine will have it's day in the sun soon enough.
Faith cures all.
MD well emphasized. Late Dr. Thorpe, Dr. Garnick, behind bavi. Double survival of SOC in P3 trial, Avid expansion probably fully implemented by late July and commercial ready for increased bavi production.
My brother in-law a Market director for a large investment firm in Orange county was in Huntington Beach, CA and spent some time with the Avid folks while he was in the area. Got the thumbs up from him.
It is on his radar screen. He personally acquired 100,000 shares so guess he is on board.
SHIP It is not out of the realm of possibility for the 1st look-in to be stopped. I am sure there are historical examples to support this.
P-value
The Haybittle–Peto boundary is a rule for deciding when to stop a clinical trial prematurely.[1]
The typical clinical trial compares two groups of patients. One group are given a placebo or conventional treatment, while the other group of patients are given the treatment that is being tested. The investigators running the clinical trial will wish to stop the trial early for ethical reasons if the treatment group clearly shows evidence of benefit. In other words, "when early results proved so promising it was no longer fair to keep patients on the older drugs for comparison, without giving them the opportunity to change."[2]
The Haybittle–Peto boundary is one such stopping rule, and it states that if an interim analysis shows a probability of less than 0.001 that the treatments are different, then the trial should be stopped early. The final analysis is still evaluated at the normal level of significance (usually 0.05).[3][4] The main advantage of the Haybittle–Peto boundary is that the same threshold is used at every interim analysis, unlike other the O'Brien–Fleming boundary, which changes at every analysis. Also, using the Haybittle–Peto boundary means that the final analysis is performed using a 0.05 level of significance as normal, which makes it easier for investigators and readers to understand. The main argument against the Haybittle–Peto boundary is that some investigators believe that the Haybittle–Peto boundary is too conservative and makes it too difficult to stop a trial.[5]
List of p-values used at each interim analysis, assuming the overall p-value for the trial is 0.05
Number of planned analyses
Interim analysis
p-value threshold
Here a link for chart:
http://en.wikipedia.org/wiki/Haybittle%E2%80%93Peto_boundary
Bavi could assist in combo based on this information:
Barriers to T cell activation and attack
Targeted cancer therapies, designed to hit specific mutations on a cancer cell, come with ready-made predictive biomarkers. Patients whose tumors have the mutation receive the targeted therapy. In contrast, immune checkpoint blockade doesn’t directly target tumors. It treats the immune system, freeing it to find and kill cells bearing recognized tumor antigens.
Immune response, the authors note, particularly regulation of T cells, consists of opposing pathways both to stimulate immune response and to inhibit it. Ipilimumab blocks a molecule on T cells called CTLA-4, which is turned on by the same binding molecules, or ligands, that stimulate a T cell response. CTLA-4’s job is to block runaway immune response.
Once a T cell attack is launched, the review notes, it then faces a variety of barriers and defenses mounted by the tumor cells, supportive tissue, regulatory T cells and other inhibitory cells, as well as chemical signaling agents in the tumor microenvironment.
slevets Who to trust? It has delineated down to Bavi and Dr. Garnick seeing it through for me. GLTA
CP
Based on this comparison the survival rate is over double with bavi just looking at the event stats. Not taking anything else EGOG etc. into account at the moment if I understand this correctly.
Correct me if I am wrong.
So in 192 Events we have a ratio of 124 Ctrl vs 67 Bavi arm events. That is 50% more Bavi Arm then the PII but still 13 patients less then the 80 that made the PII statistical significant (both Bavi arms combined).
Hey I am a relative newbie on the board but I may be hoping on the train from DC to Phily to make this.
WOOK on a more serious note not sure if I'll be going as of yet.
Apr 18–22, 2015 American Association for Cancer Research (AACR) Annual Meeting 2015
Location: Philadelphia, PA
Visit Peregrine at Booth #1908
AACR POSTER PRESENTATIONS:
Abstract Number: 274
Presentation Title: Bavituximab modulates tumor microenvironment and activates CD8+ tumor infiltrating lymphocytes in a patient-derived 3D ex vivo system of lung cancer
Abstract Number: 252
Presentation Title: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models
Abstract Number: 4289
Presentation Title: Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors
WOOK Maybe he can get them to say uncle and collaborate.
Uncle Stevie twisting their arm with DATA???????
Markets | Wed Apr 1, 2015 6:00am EDT
Related: Stocks, Currencies, M&A, Markets
Roche open to alliances in hunt for cancer drug combinations
FRANKFURT, April 1 | By Ludwig Burger and Patricia Weiss
(Reuters) - Roche, the world's largest cancer drugmaker, is ready to collaborate with rivals to find new combination therapies for multi-pronged treatments, its chief executive said.
Severin Schwan said the company was investing very heavily in a new wave of cancer immunotherapy drugs, where finding combination therapies to attack tumours on different fronts would be "extremely important".
Roche is vying with rivals such as Bristol-Myers Squibb , Merck & Co and AstraZeneca to develop such immuno-oncology therapies that harness the power of the body's immune system in the fight against cancer.
"We are open for possible forms of collaboration with external parties," Schwan told reporters late on Wednesday.
He said alliances were important even though the company had the capacity to develop drug combinations in house.
"Partnering is absolutely fundamental," he said.
Using a cocktail of two or more drugs instead of one can increase the chances of eradicating all cancerous cells in a patient's body, cutting the risk that any stray cells start dividing again after initial treatment success.
Switzerland-based Roche struck a deal in January to acquire a majority stake in molecular and genomic analysis business Foundation Medicine, to help develop combination therapies and identify cancer patients more accurately.........
The BIG BOYS are scarfing up and looking for more.
edcpf Sites continuing to open up is a good sign of things to come. IMHO
I agree with your sentiment.
FDA approval of SUNRISE coming down the pike PRINT $15 plus more to come.
GULL The wagon is staying hitched. GLTA
Have a family member attending this.
84,125 $ 1.50
(16:45:59 PM) $ 1.32
(18:39:56 PM)
AH
Yes plausible. Will see.
To anybody wishing to respond:
I know PS is flipped on the outer membrane of a dying cell and is one source of orientation for a immunosuppressive signal on the upper end. Which cancer takes advantage of so to speak.
What other known upper membrane protective measures are in play that cancer uses? Would PS be the primary protective cover utilized?
I am fairly familiar with the lower indicators.
Dr. Matthias Gromeier: So cancers, all human cancers, they develop a shield or shroud of protective measures that make them invisible to the immune system. And this is precisely what we try to reverse with our virus. So by infecting the tumor, we are actually removing this protective shield. And telling the-- enabling the immune system to come in and attack.
Jeff your statement has merit.
MD Thanks for all of your your post today. Positive information.
Seagull I am working toward 100K. Getting there. Today sure helped on buying more. However, I know many here would like it much higher right now. They have been in for a long while.
HOPE Yes, I lost about 25 LBS. Now about where I need to be. Now I need the PPS to be around $25 now.
Tech Articles come and go. What is certain we have a SUNRISE trial and I am very confident in Bavi and Dr. Garnick to see this through. In the meantime the roller coaster continues up and down with the PPS